US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio Gay-Ger, the current president and general manager of Eli Lilly China, will transition to the role of chief marketing officer and vice president of global marketing for Eli Lilly’s diabetes business. In his new role, Gay-Ger will be responsible for all diabetes products except for tirzepatide’s obesity indication. He will report to Mike Mason, senior vice president and president of Eli Lilly’s diabetes business unit. Meanwhile, Keith Johns, the current chief marketing officer for Eli Lilly diabetes markets and vice president of global marketing, will retire on December 31, 2022.
New Leadership for Eli Lilly China
Ben Basil will succeed Gay-Ger as the president and general manager of Eli Lilly China, reporting to Ilya Yuffa, senior vice president of Eli Lilly and president of Eli Lilly International. Basil is currently the president of Lilly North Asia Pacific and general manager of Australia and New Zealand. He holds a degree in molecular genetics from Ohio State University and an MBA from the University of North Carolina. Basil joined Eli Lilly in 1999 and has held various leadership positions, including global marketing director for the Eli Lilly & BI Diabetes Alliance and market leader for Lilly US oncology, Alzheimer’s, and other disease areas.-Fineline Info & Tech
